Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gogoro Inc (GGR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Gogoro IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Gogoro Inc vs Neurocrine Biosciences Inc — how do they compare? Gogoro Inc trades at $2.51 (market cap $52.19M), while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 315.4× Gogoro Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.

GGRNBIX
Market Cap
$52.19M$16.46B
Sector
TechnologyHealth
52-Week High
$7.50$185.50
52-Week Low
$2.55$123.10
Enterprise Value
$354.63M$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gogoro Inc

GGR trades at $2.63, up 1.94% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $79.97 million on $281.48 million revenue in 2025, with negative margins and cash flow, though 2026 projections show improvement. Analyst consensus is entirely hold, reflecting caution amid ongoing losses.

Outlook remains challenging with persistent losses and negative cash flow, but low P/S and P/B ratios may attract value investors if operational improvements materialize. Key risks include execution on profitability, competitive pressures, and reliance on future growth initiatives to achieve sustained positive earnings.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gogoro Inc

Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.

Read more on GGR

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX